Biovail generics, drug delivery, neurology news

Biovail is restructuring and shifting its strategic focus to CNS disorders including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer's disease (AD) and epilepsy. The company is closing two of its manufacturing facilities in Puerto Rico and reducing headcount by 250 (16%) to 1,300. The company has not decided which non-CNS programs it will abandon. Biovail markets three drugs in the U.S. to treat CNS diseases, four drugs to treat cardiovascular indications including Type II diabetes and two antivirals to treat Herpes simplex virus (HSV). ...